PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-κB in metastatic prostate cancer cells

Prostate

Volumn 69, Issue 2, 2009, Pages 168-180

  Graham, Tisheeka R ^a,b   Odero Marah, Valerie A ^b   Chung, Leland W ^b   Agrawal, Krishna C ^a   Davis, Rodney ^a   Abdel Mageed, Asim B ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

BMP 2; Bone metastasis; NF B; Prostate cancer

Indexed keywords

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMAD PROTEIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; BMP2 PROTEIN, HUMAN; BMP4 PROTEIN, HUMAN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BONE METASTASIS; CANCER CELL; CELL STRAIN LNCAP; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PLASMID; PROSTATE TUMOR; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LUCIFERASES; MALE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NF-KAPPA B; PLASMIDS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMAD PROTEINS; TRANSCRIPTION, GENETIC;

EID: 58849128722     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20870     Document Type: Article

References (55)

1. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS. Prostate carcinoma skeletal metastases: Crosstalk between tumor and bone. Cancer Metastasis Rev 2001;20:333-339.
2. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-261.
3. Hogan BL. Bone morphogenetic proteins in development. Curr Opin Genet Dev 1996;6:432-438.
4. Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 1998;16:247-252.
5. Ducy P, Schinke T, Karsenty G. The osteoblast: A sophisticated fibroblast under central surveillance. Science 2000;289:1501-1504.
6. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004;22:233-241.
7. Derynck R, Zhang Y, Feng XH. Smads: Transcriptional activators of TGF-beta responses. Cell 1998;95:737-740.
8. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000;12:235-243.
9. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000;19:1745-1754.
10. Yoshikawa H, Nakase T, Myoui A, Ueda T. Bone morphogenetic proteins in bone tumors. J Ortho Sci 2004;9:334-340.
11. Feeley BT, Krenck L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 2006;38:154-166.
12. Ye L, Lewis-Russell JM, Kynaston H, Jiang WG. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J Urol 2007;178:1086-1091.
13. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-κ correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004;90:2312-2316.
14. Ghosh S, May M, Kopp E. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
15. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappa B antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-1683.
16. Darnay BG, Aggarwal BB. Signal transduction by tumor necrosis factor and tumor necrosis factor related ligands and their receptors. Ann Rheum Dis 1999;58:I2-113.
17. Wang CY, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappa B. Nat Med 1999;5:412-417.
18. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS. NF-kappaB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia. Science 2000;289:2363-2366.
19. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenon? J Cell Biochem 2004;91:100-117.
20. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, Rabson AB. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2008;52:183-200.
21. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, Pando MP, Asano T, Verma IM, Oda H, Nakamura K, Tanaka S. Reciprocal role of ERK and NF kappaB pathways in survival and activation of osteoclasts. J Cell Biol 2000;148:333-342.
22. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: Role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res 2005;65:9891-9898.
23. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-310.
24. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188-4197.
25. Andela VB, Gordon AH, Zotalis G, Rosier RN, Goater JJ, Lewis GD, Schwartz EM, Puzas JE, O'Keefe RJ. NF kappa B: A pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res 2003;415:S75-S85.
26. Feng JQ, Xing L, Zhang JH, Zhao M, Horn D, Chan J, Boyce BF, Harris SE, Mundy GR, Chen D. NF-kappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol Chem 2003;278:29130-29135.
27. Thompson DL, Gerlach-Bank LM, Barald KF, Koenig RJ. Retinoic acid repression of bone morphogenetic protein 4 in inner ear development. Mol Cell Biol 2003;23:2277-2286.
28. Vincent F Jr, Ramanitharan A, Moparty K, Davis R, Agrawal KC, Abdel-Mageed AB. Adenovirus-mediated inhibition of NF-?B confers chemosensitization and apoptosis in prostate cancer cells via activation of caspase pathway. Int J Oncol 2003;23:317-323.
29. Davis R, Jia D, Cinar B, Sikka SC, Moparty M, Zhau HE, Chung LW, Agrawal KC, Abdel-Mageed AB. Functional androgen receptor confers sensitization of androgen independent prostate cancer cells to anticancer therapy via caspase activation. Biochem Biophy Res Commun 2003;309:937-945.
30. Abdel-Mageed AB, Agrawal KC. Activation of nuclear factor kappa B: Potential role in metallothionein-mediated mitogenic response. Cancer Res 1998;58:2335-2338.
31. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, Mundy GR. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994;24:204-211.
32. Brubaker KD, Corey E, Brown LG, Vessella RL. Bone morpho-genetic protein signaling in prostate cancer cell lines. J Cell Biochem 2004;91:151-160.
33. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, Taille A. The NF-κB/IL-6 pathway in metastatic androgen-independent prostate cancer: New therapeutic approaches? World J Urol 2007;25(5):477-489.
34. Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 1992;31:160-167.
35. Willette RN, Gu JL, Lysko PG, Anderson KM, Minehart H, Yue T. BMP-2 gene expression and effects on human vascular smooth muscle cells. J Vasc Res 1999;36:120-125.
36. Feng JQ, Xing L, Zhang JH, Zhao M, Horn D, Chan J, Boyce BF, Harris SE, Mundy GR, Chen D. NF-kappa B specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol Chem 2003;278:29130-29135.
37. Fukui N, Ikeda Y, Ohnuki T, Hikita A, Tanaka S, Yamane S, Suzuki R, Sandell LJ, Ochi T. Pro-inflammatory cytokine tumor necrosis factor-a induces bone morphogenetic protein-2 in chondrocytes via mRNA stabilization and transcriptional up-regulation. J Biol Chem 2006;281:27229-27241.
38. Eliseev RA, Schwarz EM, Zuscik MJ, O'Keefe RJ, Drissi H, Rosier RN. Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NF- kappa B. Exp Cell Res 2006;312:40-50.
39. Madrid LV, Mayo MW, Reuther JY, Baldwin AS Jr. Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38. J Biol Chem 2001;276:18934-18940.
40. Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: Role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation 2005;111:2364-2372.
41. Li X, Massa PE, Hanidu A, Peet GW, Aro P, Savitt A, Mische S, Marcu KB. IKKα, IKKβ, and NEMO/IKKγ are each required for the NF-κB-mediated inflammatory response program. J Biol Chem 2002;277:45129-45140.
42. Chen D, Harris MA, Rossini G, Dunstan CR, Dallas SL, Feng JQ, Mundy GR, Harris SE. Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif Tissue Int 1997;60:283-290.
43. Pereira RC, Rydziel S, Canalis E. Bone morphogenetic protein-4 regulates its own expression in cultured osteoblasts. J Cell Physiol 2000;182:239-246.
44. Yingling JM, Datto MB, Wong C, Frederick JP, Liberati NT, Wang XF. Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein. Mol Cell Biol 1997;17:7019-7028.
45. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern SE. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998;1:611-617.
46. Derynck R, Zhang Y, Feng XH. Smads: Transcriptional activators of TGF-b responses. Cell 1998;95:737-740.
47. Nishimura R, Kato Y, Chen D, Harris SE, Mundy GR, Yoneda T. Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesen-chymal precursor cell line C2C12. J Biol Chem 1998;273:1872-1879.
48. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000;14:627-644.
49. Spinella-Jaegle S, Roman-Roman S, Faucheu C, Dunn FW, Kawai S, Gallea S, Stiot V, Blanchet AM, Courtois B, Baron R, Rawadi G. Opposite effects of bone morphogenetic protein-2 and transforming growth factor-betal on osteoblast differentiation. Bone 2001;29:323-330.
50. Ghosh-Choudhury N, Abboud SL, Nishimura R, Celeste A, Mahimainathan L, Choudhury GG. Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threo-nine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription. J Biol Chem 2002;277:33361-33368.
51. Osyczka AM, Leboy PS. Bone morphogenetic protein regulation of early osteoblast genes in human marrow stromal cells is mediated by extracellular signal-regulated kinase and phospha-tidylinositol 3-kinase signaling. Endocrinology 2005;146:3428-3437.
52. Noth U, Tuli R, Seghatoleslami R, Howard M, Shah A, Hall DJ, Hickok NJ, Tuan RS. Activation of p38 and Smads mediates BMP-2 effects on human trabecular bone-derived osteoblasts. Exp Cell Res 2003;291:201-211.
53. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI, Knaus P. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 2002;277:5330-5338.
54. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127-133.
55. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004;90:2312-2316.